| Old Articles: <Older 2821-2830 Newer> |
|---|
 |
Fast Company
April 2006
Chuck Salter |
A Prescription for Innovation The Mayo Clinic's new SPARC lab is driving experimentation at the frontier of health care. How? By getting physicians to think more like designers.   |
Fast Company
April 2006
Michael A. Prospero |
Top Scalpel Too many medical errors happen because of lousy communications. To help fix that, health care is looking to the skies. |
The Motley Fool
April 12, 2006
Stephen D. Simpson |
Danaher Polishes Off Sybron The multifaceted conglomerate is paying a lot to expand its footprint in the dental market. Under the terms of the deal, which Sybron supports, shareholders will get $47 in cash for each share -- about a 12% premium. |
The Motley Fool
April 12, 2006
Stephen D. Simpson |
Genentech Is Weird Genentech is undoubtedly a great biotech, but it seems like Wall Street obsesses about the wrong things. Investors, take note. |
The Motley Fool
April 11, 2006
Rick Aristotle Munarriz |
Bausch & Lomb Sees Eye to Ay The contact lens specialist gets tripped up over its potentially infected ReNu brand. Bausch & Lomb's stock took a 9% hit in after-hours trading on the news. |
The Motley Fool
April 10, 2006
Stephen D. Simpson |
Serono Stands Alone Is management of the Swiss-based biotech serving shareholders' interests, or being stubborn? Investors, take note. |
The Motley Fool
April 10, 2006
Rich Duprey |
Merck Splits the Difference The pharmaceutical wins one, loses one in New Jersey Vioxx trials. Investors should expect to see more losses. |
BusinessWeek
April 17, 2006
Amy Barrett |
J&J: Reinventing How It Invents Johnson & Johnson bets on a new push for product development as a cure for its ailing stock. |
BusinessWeek
April 17, 2006
Amy Barrett |
Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created. |
The Motley Fool
April 5, 2006
David Compton |
3M's Pharma Unit for Sale The branded-drugs unit is on the block, and Wall Street likes the move. It allows 3M to focus on its core strengths, and the branded drugs will be much better marketed by a large pharmaceutical company. |
| <Older 2821-2830 Newer> Return to current articles. |
